Wird geladen...
LAG3 (CD223) as a Cancer Immunotherapy Target
Despite the impressive impact of CTLA4 and PD1-PDL1 targeted cancer immunotherapy, a large proportion of patients with many tumor types fail to respond. Consequently, the focus has shifted to targeting alternative inhibitory receptors (IRs) and suppressive mechanisms within the tumor microenvironmen...
Gespeichert in:
| Veröffentlicht in: | Immunol Rev |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5338468/ https://ncbi.nlm.nih.gov/pubmed/28258692 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imr.12519 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|